Abstract
4098 Background: After Sorafenib failure,there is no effective systemic therapy for advanced HCC. Preclinical data show upregulated mTOR signaling in HCC. We tested the IV mTOR inhibitor (i), Temsi...
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
